-
钠碘同向转运体(sodium iodide symporter, NIS)是甲状腺细胞中介导碘摄取的膜蛋白,在其他组织中如唾液腺、胃黏膜及泌乳期乳腺等也有所表达。1996年,Dai等[1]首次得到了鼠源性NIS cDNA,在此基础上,Smanik等[2]成功克隆了人源性NIS基因。通过外界诱导肿瘤组织自身NIS的表达或利用载体将NIS基因特异性转染到肿瘤细胞,使其能够摄取发射γ射线的放射性核素或发射具有组织杀伤力的高能β射线的放射性核素,可为肿瘤显像和肿瘤治疗提供新途径。多项研究已成功将外源性NIS基因导入前列腺癌、黑色素瘤、胶质瘤及骨髓瘤等细胞,获得了NIS蛋白的表达。但目前尚存在核素在细胞内滞留时间短的问题,影响了疗效。本文综述了近年来在NIS相关机制研究、提高NIS表达及摄碘率、延长其在细胞内滞留时间等改进基因治疗疗效方面的新进展。
钠碘同向转运体基因介导放射性碘治疗肿瘤的研究进展
Advances of radioiodine therapy of tumor induced by sodium iodide symporter gene
-
摘要: 钠碘同向转运体(NIS)作为一种细胞膜蛋白,主要存在于甲状腺滤泡细胞基底膜并介导细胞的碘转运,在甲状腺癌及非甲状腺癌的放射性碘治疗研究中备受关注。部分甲状腺癌的NIS表达水平降低或者膜蛋白定位不好,通过导入NIS基因进行膜表达,介导核素滞留于细胞内,是肿瘤治疗的新途径。但目前主要存在核素在细胞内滞留时间短而影响疗效的问题。对此,在导入NIS基因后,可通过各种方法刺激肿瘤细胞增加NIS的功能性表达而增加核素的摄取,也可通过减少核素的流出来提高其滞留,扩展NIS基因治疗的应用范围,优化肿瘤治疗。该文主要综述了NIS基因介导的肿瘤治疗研究进展。Abstract: As a kind of membrane protein that mainly mediates iodide transport into thyroid follicular cells, sodium iodide symporter(NIS) plays a key role in radioiodine therapy of both thyroid and other cancers. Studies show that decreased NIS expression level or intracellular localization in thyroid carcinomas lead to low iodine uptake. So NIS gene therapy is a new method to overcome this problem. To be therapeutically effective, radioiodine has to be remained in the tumor cells for sufficient long time; this is still a problem which reduces therapeutic effect. It should increase iodide retention and decrease iodide efflux in tumor cells to optimize therapeutic scheme. This article reviews the studies on advances of radioiodine therapy of tumor induced by sodium iodide symporter gene.
-
Key words:
- Iodine radioisotopes /
- Thyroid neoplasms /
- Gene therapy /
- Sodium iodide symporter
-
[1] Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature, 1996, 379(6564): 458-460. doi: 10.1038/379458a0 [2] Smanik P, Liu Q, Furminger TL, et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun, 1996, 226(2): 339-345. doi: 10.1006/bbrc.1996.1358 [3] Scott DA, Wang R, Kreman TM, et al. The Pendred syndrome gene encodes a chloride-iodide transport protein. Nat Genet, 1999, 21(4): 440-443. doi: 10.1038/7783 [4] Rodriguez AM, Perron B, Lacroix L, et al. Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab, 2002, 87(7): 3500-3503. doi: 10.1210/jcem.87.7.8797 [5] Lazar V, Bidart JM, Caillou B, et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab, 1999, 84(9): 3228-3234. [6] Dohán O, Baloch Z, Bánrévi Z, et al. Rapid communieation: predominant intracellular overexpression of the Na+/I- symporter (NIS) in a large sampling of thyroid cancer case. J Clin Endocrinol Metab, 2001, 86(6): 2697-2700. [7] De La Vieja A, Dohán O, Levy O, et al. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev, 2000, 80(3): 1083-1105. doi: 10.1152/physrev.2000.80.3.1083 [8] Yokomori N, Tawata M, Saito T, et al. Regulation of the rat thyrotropin receptor gene by the methylation-sensitive transcription factor GA-binding protein. Mol Endocrinol, 1998, 12(8): 1241-1249. doi: 10.1210/mend.12.8.0142 [9] Peyrottes I, Navarro V, Ondo-Mendez A, et al. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. Eur J Endocrinol, 2009, 160(2): 215-225. doi: 10.1530/EJE-08-0505 [10] Venkataraman GM, Yatin M, Marcinek R, et al. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I- symporter gene methylation status. J Clin Endocrinol Metab, 1999, 84(7): 2449-2457. [11] Kitazono M, Robey R, Zhan Z, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide(FR901228), increase expression of the Na+/I- symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab, 2001, 86(7): 3430-3435. [12] Zarnegar R, Brunaud L, Kanauchi H, et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery, 2002, 132(6): 984-990. doi: 10.1067/msy.2002.128690 [13] Simon D, Körber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging, 2002, 29(6): 775-782. doi: 10.1007/s00259-001-0737-6 [14] Haugen BR, Larson LL, Pugazhenthi U, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab, 2004, 89(1): 272-280. doi: 10.1210/jc.2003-030770 [15] Kogai T, Schultz JJ, Johnson LS, et al. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci USA, 2000, 97(15): 8519-8524. doi: 10.1073/pnas.140217197 [16] Kim KI, Kang JH, Chung JK, et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med, 2007, 48(9): 1553-1561. doi: 10.2967/jnumed.106.038612 [17] Condreay JP, Witherspoon SM, Clay WC, et al. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA, 1999, 96(1): 127-132. doi: 10.1073/pnas.96.1.127 [18] Mian C, Barollo S, Pennelli G, et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf), 2008, 68(1): 108-116. doi: 10.1111/j.1365-2265.2007.03008.x [19] Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab, 2007, 92(7): 2840-2843. doi: 10.1210/jc.2006-2707 [20] Furuya F, Shimura H, Miyazaki A, et al. Adenovirus-mediated transfer of thyroid transcription factor-1 induces radioiodide organ-ification and retention in thyroid cancer cells. Endocrinology, 2004, 145(11): 5397-5405. doi: 10.1210/en.2004-0631 [21] Huang M, BatraRK, Kogai T, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther, 2001, 8(8): 612-618. doi: 10.1038/sj.cgt.7700354 [22] Boland A, Magnon C, Filetti S, et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid, 2002, 12(1): 19-26. doi: 10.1089/105072502753451922 [23] Elisei R, Vivaldi A, Ciampi R, et al. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular reten-tion time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab, 2006, 91(6): 2389-2395. doi: 10.1210/jc.2005-2480 [24] Yoon JK, Park BN, Paik JY, et al. Effects of theophylline on radioiodide uptake in MCF-7 breast cancer and NIS gene-transduced SNU-C5 colon cancer cells. Cancer Biother Radiopharm, 2009, 24(2): 201-208. doi: 10.1089/cbr.2008.0555 [25] Lee JM, Zemans RL, Hejazi M, et al. Modulation of thyroidal radioiodine uptake by theophylline. Exp Mol Pathol, 2004, 77(2): 116-120. doi: 10.1016/j.yexmp.2004.05.002 [26] Dingli D, Bergert ER, Bajzer Z, et al. Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun, 2004, 325(1): 157-166. doi: 10.1016/j.bbrc.2004.09.219 [27] Nakamoto Y, Saga T, Misaki T, et al. Establishment and charac-terization of a breast cancer cell line expressing Na+/I-symporters for radioiodide concentrator gene therapy. J Nucl Med, 2000, 41(11): 1898-1904. [28] Smit JW, Schröder-van der Elst JP, Karperien M, et al. Iodide kinetics and experimental 131I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carinoma cell line. J Clin Endocrinol Metab, 2002, 87(3): 1247-1253. doi: 10.1210/jcem.87.3.8307 [29] Josefsson M, Evilevitch L, Weström B, et al. Sodium-iodide sym-porter mediates iodide secretion in rat gastric mucosa in vitro. Exp Biol Med (Maywood), 2006, 231(3): 277-281. doi: 10.1177/153537020623100306
计量
- 文章访问数: 1056
- HTML全文浏览量: 586
- PDF下载量: 2